4.7 Article

Molecular Targeted NIR-II Probe for Image-Guided Brain Tumor Surgery

期刊

BIOCONJUGATE CHEMISTRY
卷 29, 期 11, 页码 3833-3840

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.bioconjchem.8b00669

关键词

-

资金

  1. Office of Science (BER), U.S. Department of Energy [DE-SC0008397]
  2. Lundbeck Foundation
  3. European Union's EU Framework
  4. Programme for Research and Innovation Horizon 2020
  5. European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [670261]
  6. Novo Nordisk Foundation
  7. Innovation Fund Denmark
  8. Neye Foundation
  9. Research Council for Independent Research
  10. Righospitalet Research Council
  11. Research Fund of the Capital Region of Denmark

向作者/读者索取更多资源

Optical imaging strategies for improving delineation of glioblastoma (GBM) is highly desired for guiding surgeons to distinguish cancerous tissue from healthy and precious brain tissue. Fluorescence imaging (FLI) in the second near-infrared window (NIR-II) outperforms traditional NIR-I imaging with better tissue penetration, higher spatial and temporal resolution, and less auto fluorescence and scattering. Because of high expression in GBM and many other tumors, urokinase Plasminogen Activator Receptor (uPAR) is an attractive and well proven target for FLI. Herein we aim to combine the benefit of a NIR-II fluorophore with a high affinity uPAR targeting small peptide. A targeted NIR-II fluorescent probe was developed by conjugating an in-house synthesized NIR-II fluorophore, CH1055, and a uPAR targeting peptide, AE105. To characterize the in vivo distribution and targeting properties, a dynamic imaging was performed in orthotopic GBM bearing nude mice (n = 8). Additionally, fluorescence guided surgery of orthotopic GBM was performed in living animals. CH1055-4Glu-AE105 was easily synthesized with >75% yield and >98% HPLC evaluated purity. The retention time of the probe on analytical HPLC was 15.9 min and the product was verified by mass spectrometry. Dynamic imaging demonstrated that the uPAR targeting probe visualized orthotopic GBM through the intact skull with a tumor-to-background ratio (TBR) of 2.7 peaking at 96 h. Further, the orthotopic GBM was successfully resected in small animals guided by the NIR-II FLI. By using a small uPAR targeting NIR-II probe, FLI allows us to specifically image and detect GBM. A real-time imaging setup further renders FLI guided tumor resection, and the probe developed in this work is a promising candidate for clinical translation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据